← The Wire
LNTHNasdaq
Lantheus Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · DE · CIK 1521036
Lantheus Holdings enables clinicians to find, fight, and follow disease with radiopharmaceuticals and precision diagnostics
red 8-K · 90d
$6.80B
Market cap
$109.58
Last close
-0.2%
1D
+3.2%
5D
1.3M
Volume
Price · last 39 sessions+24.8%
May 4L $85.82 · H $109.80Jun 29
249
Total filings
May 7, 2026
Last filing
12/31
Fiscal year end
10-Q10-QMay 7, 20268-KResults of OperationsMay 7, 20268-KExecutive Change · Security-Holder RightsMay 1, 2026DEFA14ADEFA14AMar 20, 2026DEF 14ADEF 14AMar 20, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KExecutive ChangeNov 12, 202510-Q10-QNov 6, 20258-KExecutive Change · Results of OperationsNov 6, 20258-KExecutive ChangeAug 11, 202510-Q10-QAug 6, 20258-KResults of Operations · Reg FD DisclosureAug 6, 20258-KAcquisition / Disposition · Reg FD DisclosureJul 22, 202510-Q10-QMay 7, 20258-KResults of OperationsMay 7, 20258-KBylaw Amendment · Shareholder VoteMay 5, 20258-KAcquisition / Disposition · Reg FD DisclosureApr 1, 2025DEFA14ADEFA14AMar 21, 2025DEF 14ADEF 14AMar 21, 202510-K10-KFeb 26, 20258-KResults of OperationsFeb 26, 20258-KExecutive ChangeJan 30, 20258-KMaterial Agreement · Results of OperationsJan 28, 20258-KMaterial Agreement · Reg FD DisclosureJan 13, 20258-KMaterial Agreement · New Debt / ObligationDec 23, 20248-KReg FD DisclosureDec 19, 20248-KCompany UpdateNov 20, 2024SC 13GSC 13GNov 14, 202410-Q10-QNov 6, 20248-KResults of OperationsNov 6, 20248-KReg FD DisclosureSep 25, 20248-KExecutive ChangeSep 5, 202410-Q10-QJul 31, 20248-KResults of OperationsJul 31, 20248-KReg FD DisclosureJun 27, 20248-KExecutive ChangeJun 24, 20248-KExecutive ChangeMay 15, 202410-Q10-QMay 2, 20248-KResults of OperationsMay 2, 20248-KExecutive Change · Shareholder VoteApr 29, 2024DEFA14ADEFA14AMar 15, 2024DEF 14ADEF 14AMar 15, 202410-K10-KFeb 22, 20248-KResults of OperationsFeb 22, 20248-KReg FD DisclosureJan 26, 20248-KExecutive ChangeJan 23, 20248-KResults of OperationsJan 9, 202410-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KExecutive ChangeAug 28, 20238-KCompany UpdateAug 18, 202310-Q10-QAug 3, 20238-KResults of Operations · Reg FD DisclosureAug 3, 20238-KMaterial Agreement · New Debt / ObligationMay 4, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 20238-KExecutive Change · Shareholder VoteMay 1, 20238-K/AExecutive ChangeMar 20, 20238-KExecutive ChangeMar 17, 2023DEFA14ADEFA14AMar 17, 2023DEF 14ADEF 14AMar 17, 202310-K10-KFeb 23, 20238-KResults of OperationsFeb 23, 20238-KReg FD DisclosureFeb 6, 20238-KReg FD DisclosureJan 11, 20238-KBylaw AmendmentDec 28, 20228-KAcquisition / Disposition · Company UpdateDec 20, 20228-KMaterial Agreement · New Debt / ObligationDec 8, 20228-KCompany UpdateDec 6, 20228-KMaterial Agreement · Agreement TerminatedDec 5, 20228-KMaterial Agreement · Company UpdateNov 14, 202210-Q10-QNov 3, 20228-KResults of OperationsNov 3, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KExecutive ChangeJun 15, 20228-KReg FD DisclosureMay 17, 20228-KExecutive Change · Shareholder VoteMay 2, 202210-Q10-QApr 29, 2022
In the News
ReutersLantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance